Nanoligent

About:

Nanoligent aim is the research and development to clinical phases of innovative cancer treatments based on protein nanoparticles.

Website: http://www.nanoligent.com/

Top Investors: IAG Capital Partners, i&i Biotech Fund, AVANTECA Partners

Description:

Nanoligent is a biotech company, spin-off of the Universitat Autònoma de Barcelona (UAB) and Institut de Recerca de l'Hospital de la Santa Creu I Sant Pau. We are dedicated to drug design and development of targeted-therapeutic biologics .Nanoligent mision is to improve the life of patients by designing new medicines that selectively target the cells affected by disease. With this approach we develope treatments that are more effective and have fewer adverse effects than classical drugs.